Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
| Previous close | 10.720 |
| Open | 10.840 |
| Bid | 10.720 x N/A |
| Ask | 10.820 x N/A |
| Day's range | 10.440 - 10.860 |
| 52-week range | 7.200 - 14.660 |
| Volume | |
| Avg. volume | 229,276 |
| Market cap | 3.51B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.260 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.57 |
Simply Wall St.SEHK Growth Companies With Up To 38% Insider Ownership
In recent trading sessions, the Hong Kong market has shown positive momentum, with the Hang Seng Index climbing 2.64%, reflecting a buoyant mood spurred by strong holiday spending and recovery hopes. This backdrop provides an interesting context for examining growth companies in Hong Kong, particularly those with high insider ownership, which can be a marker of confidence in the company's future from those who know it best.
PR NewswireZylox-Tonbridge Announces Annual Financial Results for 2023, Demonstrating Robust Growth and Improved Profitability
Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial results for 2023. The report underlines a year of remarkable revenue growth and profitability, with revenues soaring to 530 million RMB ($75 million), marking a 58.0% YOY increase. The gross profit increased 52.4% to 380 million RMB ($54 million), with the company maintaining a solid gross margin of 72.9%. Wit
PR NewswireZylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions
Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in China, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease. This partnership includes an exclusive right to Zylox-Tonbridge to localize, manufacture, and commercialize the
